Cekelan dhuwit saben saham Apollomics (APLM)

This cash per share chart demonstrates the liquidity of Apollomics, Inc. (APLM), where the latest mark stands at 0.35. Apollomics, Inc. (APLM) is focusing on launching webreltinib in the US and Chinese markets for the therapy of solid tumors. The company delegates the production of candidates to external CDMO centers, while conducting research in its own hubs. High patent requirements and rigorous FDA tests ensure robust intellectual property protection.
Rincian analitis perusahaan Apollomics, Inc.

During periods of market volatility, it is critical for investors to assess an asset's intrinsic resilience. The possession of unique patents for c-Met inhibitors and the successful navigation of stringent FDA filters ensure the long-term competitiveness of Apollomics, Inc. (APLM). This metric is calculated as the ratio of net liquidity to the number of shares, determining the actual value of a single share in cash equivalents. The cash per share trend for the issuer on GURU.Markets visualizes the pace of reserve accumulation. A rising indicator reduces investment risks, bringing the market price closer to its fundamental basis.